HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Monday, 7 February 2011

NICE TA for peripheral arterial disease

NICE has published draft guidance recommending the use of naftidrofuryl oxalate as a treatment option for people who suffer from intermittent claudication.  The work for this appriasal was undertaken by a team of researchers from HEDS - Hazel Squires, Emma Simpson, Yang Meng, Sue Harnan, John Stevens and Ruth Wong.  NICE report that “the evidence considered by the Appraisal Committee showed that the others - Cilostazol (Pletal, Otsuka Pharmaceuticals), Pentoxifylline (Trental 400, Sanofi-Aventis) and Inositol nicotinate (Hepoxal, Genus Phamaceuticals) - are not as clinically or cost effective as naftidrofuryl oxalate so they are not recommended as treatment options in the draft guidance”.

The ERG report -  Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease - is available online and is a classic piece of HTA including a comprehensive search of the literature, a systematic review, a novel network meta-analysis and a de novo cost-effectiveness model.

Further details are available from Hazel Squires.